QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
NASDAQ:ARGX

argenx (ARGX) Stock Price, News & Analysis

$393.39
-5.20 (-1.30%)
(As of 02:56 PM ET)
Today's Range
$393.00
$397.79
50-Day Range
$356.95
$411.20
52-Week Range
$327.73
$550.76
Volume
134,662 shs
Average Volume
348,612 shs
Market Capitalization
$23.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$530.74

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
34.9% Upside
$530.74 Price Target
Short Interest
Healthy
2.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of argenx in the last 14 days
Based on 29 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.07) to $3.53 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.30 out of 5 stars

Medical Sector

307th out of 938 stocks

Biological Products, Except Diagnostic Industry

43rd out of 154 stocks

ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

argenx (NASDAQ:ARGX) Given Buy Rating at HC Wainwright
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Key Takeaways From argenx Analyst Ratings
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Reasons to Invest in argenx (ARGX)
argenx NV ADR (ARGX)
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
Argenx price target raised by $56 at Scotiabank, here's why
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$530.74
High Stock Price Target
$641.00
Low Stock Price Target
$408.00
Potential Upside/Downside
+33.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
21 Analysts

Profitability

Net Income
$-295,050,000.00
Pretax Margin
-24.00%

Debt

Sales & Book Value

Annual Sales
$1.27 billion
Book Value
$69.22 per share

Miscellaneous

Free Float
57,861,000
Market Cap
$23.64 billion
Optionable
Optionable
Beta
0.65
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 52)
    M.B.A., M.Sc., CEO & Executive Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 54)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 54)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 39)
    Vice President of Corporate Development & Strategy
  • Ms. Andria Wilk (Age 50)
    Global Head of Quality
  • Mr. Luc Truyen (Age 59)
    Chief Medical Officer
  • Ms. Karen Massey (Age 45)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 44)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenx was last updated on Monday, March 25, 2024 at 11:27 AM.

Pros

Here are some ways that investors could benefit from investing in argenx SE:

  • argenx stock price has shown resilience, currently trading at a level that presents a potential buying opportunity.
  • Positive analyst ratings and target price adjustments from reputable firms like Raymond James and Wells Fargo & Company indicate confidence in the company's future performance.
  • Recent growth in institutional investments, such as Schonfeld Strategic Advisors LLC increasing its stake by 421.6%, can signal strong market sentiment towards argenx.
  • argenx's revenue of $417.84 million for the last quarter exceeded analysts' expectations, showcasing the company's revenue-generating capabilities.
  • argenx's 52-week high of $550.76 suggests potential for capital appreciation if the stock returns to previous highs.

Cons

Investors should be bearish about investing in argenx SE for these reasons:

  • argenx reported a negative return on equity of 30.97% and a negative net margin of 23.26%, indicating financial challenges that may impact investor returns.
  • Deutsche Bank AG significantly reduced its holdings in argenx by 95.5% in the third quarter, which could raise concerns about the company's future performance.
  • Evercore ISI lowered its target price on argenx, signaling potential risks or challenges ahead for the company.
  • argenx's 12-month low of $327.73 may indicate volatility in the stock price, posing risks for short-term investors.
  • The company's PE ratio of -98.44 suggests that argenx is currently not profitable, which could deter some investors seeking immediate returns.

ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

21 brokerages have issued 1-year target prices for argenx's shares. Their ARGX share price targets range from $408.00 to $641.00. On average, they anticipate the company's stock price to reach $530.74 in the next year. This suggests a possible upside of 34.9% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2024?

argenx's stock was trading at $380.43 at the start of the year. Since then, ARGX shares have increased by 3.4% and is now trading at $393.39.
View the best growth stocks for 2024 here
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) released its quarterly earnings data on Thursday, February, 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.45. The business earned $417.84 million during the quarter, compared to analyst estimates of $378.60 million. argenx had a negative net margin of 23.26% and a negative trailing twelve-month return on equity of 16.97%. During the same quarter in the prior year, the firm posted ($0.70) earnings per share.

What guidance has argenx issued on next quarter's earnings?

argenx issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $374.0 million-$374.0 million, compared to the consensus revenue estimate of $358.9 million.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.21%), Artisan Partners Limited Partnership (5.36%), Capital World Investors (3.31%), Avoro Capital Advisors LLC (2.09%), Bellevue Group AG (1.47%) and RTW Investments LP (1.13%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners